Dataset Information


Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

ABSTRACT: Hepatocellular carcinoma (HCC) is a heterogeneous cancer with active Wnt signaling. Underlying biologic mechanisms remain unclear and no drug targeting this pathway has been approved to date. We aimed to characterize Wnt-pathway aberrations in HCC patients, and to investigate sorafenib as a potential Wnt modulator in experimental models of liver cancer.The Wnt-pathway was assessed using mRNA (642 HCCs and 21 liver cancer cell lines) and miRNA expression data (89 HCCs), immunohistochemistry (108 HCCs), and CTNNB1-mutation data (91 HCCs). Effects of sorafenib on Wnt signaling were evaluated in four liver cancer cell lines with active Wnt signaling and a tumor xenograft model.Evidence for Wnt activation was observed for 315 (49.1%) cases, and was further classified as CTNNB1 class (138 cases [21.5%]) or Wnt-TGF? class (177 cases [27.6%]). CTNNB1 class was characterized by upregulation of liver-specific Wnt-targets, nuclear ?-catenin and glutamine-synthetase immunostaining, and enrichment of CTNNB1-mutation-signature, whereas Wnt-TGF? class was characterized by dysregulation of classical Wnt-targets and the absence of nuclear ?-catenin. Sorafenib decreased Wnt signaling and ?-catenin protein in HepG2 (CTNNB1 class), SNU387 (Wnt-TGF? class), SNU398 (CTNNB1-mutation), and Huh7 (lithium-chloride-pathway activation) cell lines. In addition, sorafenib attenuated expression of liver-related Wnt-targets GLUL, LGR5, and TBX3. The suppressive effect on CTNNB1 class-specific Wnt-pathway activation was validated in vivo using HepG2 xenografts in nude mice, accompanied by decreased tumor volume and increased survival of treated animals.Distinct dysregulation of Wnt-pathway constituents characterize two different Wnt-related molecular classes (CTNNB1 and Wnt-TGF?), accounting for half of all HCC patients. Sorafenib modulates ?-catenin/Wnt signaling in experimental models that harbor the CTNNB1 class signature.

PROVIDER: S-EPMC3446854 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7268324 | BioStudies
2019-01-01 | S-EPMC6826293 | BioStudies
2017-01-01 | S-EPMC5371438 | BioStudies
2019-09-27 | GSE137787 | GEO
2019-09-27 | GSE137784 | GEO
2019-01-01 | S-EPMC6677618 | BioStudies
1000-01-01 | S-EPMC535370 | BioStudies
| S-EPMC5073058 | BioStudies
2016-01-01 | S-EPMC5192070 | BioStudies
1000-01-01 | S-EPMC5342721 | BioStudies